News
AMRN
14.09
+0.21%
0.03
Amarin Price Target Announced at $13.00/Share by JP Morgan
Dow Jones · 5h ago
JP Morgan Reinstates Underweight on Amarin Corp, Announces $13 Price Target
Benzinga · 5h ago
Amarin reinstated with an Underweight at JPMorgan
TipRanks · 14h ago
Weekly Report: what happened at AMRN last week (0810-0814)?
Weekly Report · 4d ago
Weekly Report: what happened at AMRN last week (0803-0807)?
Weekly Report · 08/10 09:22
Weekly Report: what happened at AMRN last week (0727-0731)?
Weekly Report · 08/03 09:22
Amarin Earnings Call: Cost Cuts, Cash Strength, Mixed Sales
TipRanks · 08/02 00:13
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short
NASDAQ · 07/29 16:17
Amarin Q2 Earnings Call Highlights
NASDAQ · 07/29 13:03
Amarin misses Q2 topline estimates
Seeking Alpha · 07/29 11:07
Amarin Corp Q2 Sales $42.211M Miss $44.550M Estimate
Benzinga · 07/29 11:04
Here are the major earnings before the open Wednesday
Seeking Alpha · 07/28 22:00
Amarin Q2 Earnings Preview
Seeking Alpha · 07/28 14:21
Weekly Report: what happened at AMRN last week (0720-0724)?
Weekly Report · 07/27 09:23
Weekly Report: what happened at AMRN last week (0713-0717)?
Weekly Report · 07/20 09:22
Here's Why You Should Add INKT Stock to Your Portfolio Now
NASDAQ · 07/16 16:24
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
NASDAQ · 07/13 13:03
Weekly Report: what happened at AMRN last week (0706-0710)?
Weekly Report · 07/13 09:23
Amarin: The Market Is Pricing A 55% Chance Of A Sale That Isn't Coming
Seeking Alpha · 07/07 12:58
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 07/07 12:05
More
Webull provides a variety of real-time AMRN stock news. You can receive the latest news about Amarin through multiple platforms. This information may help you make smarter investment decisions.
About AMRN
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.